Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A shipment of COVID-19 vaccines at the international airport of Accra, Ghana, on Feb. 24, 2021.

FRANCIS KOKOROKO/Reuters

The COVAX vaccine-sharing program said on Tuesday it will deliver 237 million doses of AstraZeneca’s COVID-19 shot to 142 countries by the end of May as it steps up the global rollout of its vaccine supplies.

The timeline for the delivery of doses, made by AstraZeneca and by India’s Serum Institute, will be split into separate two-month schedules, COVAX said in a statement, with the first in February-March and the second in April-May.

“These timelines are dependent on a variety of factors including national regulatory requirements, availability of supply, and fulfilment of other criteria such as validated national deployment and vaccination plans,” the statement said.

Story continues below advertisement

COVAX is the program backed by the World Health Organization and GAVI vaccine alliance to provide vaccines for poor and middle-income countries. It began its rollout last week with the first deliveries of shots to Ghana and Ivory Coast.

“It can’t be overemphasized enough that we are undertaking the largest and most complex vaccine rollout in history,” Seth Berkley, GAVI chief executive officer, told a news conference.

“We are just starting, but we should see more and more countries being served in coming weeks and months including those at all income levels and across the world,” he said.

Hailing the campaign as an “unprecedented partnership,” WHO Director-General Tedros Adhanom Ghebreyesus said Angola, Cambodia, Democratic Republic of Congo and Nigeria could also expect deliveries of COVAX-supplied vaccines on Tuesday.

“This is an unprecedented partnership that will not only change the course of the pandemic but also change the way the world responds to future health emergencies,” Tedros said.

Ghanaian President Nana Akufo-Addo told the same briefing that his West African country, which this week began its inoculation campaign with COVAX doses, aimed to vaccinate 20 million people by the end of 2021.

The COVAX statement said that as well as the first round of allocations of the AstraZeneca vaccine, some 1.2 million doses of the Pfizer-BioNTech shot were also anticipated for delivery in the first quarter of 2021.

Story continues below advertisement

COVAX hoped to finalize a deal with Novavax for 1.1 billion doses in coming weeks, Berkley said.

The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies. Reuters

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies